2025 will be the year of cagrisema. Of all the drugs expected to launch next year, Novo Nordisk A/S’s GLP-1/amylin combo carries the greatest sales forecasts – and by a long, long way.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?